Due to fedratinib's significant GI side effect profile and the logistical difficulty of measuring thiamine levels, clinicians should proactively provide patients with thiamine supplements, anti-emetics, and anti-diarrheal therapies. Instructing patients to take the drug with food can also help mitigate GI toxicity.

The failure of an adjuvant trial for the TKI pazopanib was likely caused by a protocol change that reduced the dose to manage transaminitis. While well-intentioned to improve tolerability and adherence, the lower dose was sub-therapeutic. This serves as a critical lesson that managing side effects by compromising dose can nullify a drug's potential efficacy.

Clinicians may counsel patients towards therapies with lower efficacy if the dosing schedule is more convenient (e.g., quarterly). The rationale is that a lack of response is evident quickly, allowing a rapid pivot to another treatment without losing significant time or risking progression.

A patient's reminder that even clinically-graded "mild" side effects like grade 2 diarrhea can be debilitating highlights a disconnect between clinical assessment and patient experience. This underscores the need for oncologists to consider the real-world impact of toxicities, like the ability to leave the house, when choosing a treatment regimen.

The selection between PARP inhibitors like olaparib and niraparib is not one-size-fits-all. It's a personalized decision based on patient preference for dosing frequency (once vs. twice daily), tolerance for side effects like hypertension, and potential drug-drug interactions.

Dr. Smith highlights a critical flaw in pharmacology: while a single drug undergoes rigorous FDA testing, there is zero data on the interactive effects when a patient takes two or more drugs concurrently. This 'polypharmacy' creates unpredictable and potentially harmful side effects.

New targeted therapies like Zanidatamab and Zolbetuximab show great promise but cause significant side effects like diarrhea and nausea. Their successful clinical adoption hinges on proactive management using detailed guidelines and prophylactic medications, as toxicity can be severe enough to force treatment discontinuation despite the drug's efficacy.

When a toxicity like rash occurs with EV+pembrolizumab—which could be caused by either drug—the recommended strategy is to stop both. After the rash improves, reintroduce the drug least suspected of causing it first. If the rash does not recur, it helps confirm the other agent was the culprit.

Contrary to the assumption that combinations are more toxic, Lenvatinib/Belzutifan showed a different side effect profile, not a worse one, compared to single-agent Cabozantinib. The combo caused more anemia while Cabozantinib caused more diarrhea and skin toxicity, but treatment discontinuation rates were identical at 11% for both arms.